Abstract 1570P
Background
New breast cancer (BC) cases in county regions, including rural areas, account for 33% of all BC cases annually in China. Women residing in county areas generally have lower economic income and educational levels compared to urban women, lacking the access to medical resources. We utilized real-world data to explore the factors and impacts of delayed presentation for BC patients (pts) in county areas.
Methods
CHASE001 (NCT05544123) was an observational, multicenter study assessing real-world treatment patterns among BC pts in county areas of China. Descriptive statistics reported patient intervals and demographics. Multivariate regression analyses (MVA) and rank-sum test were used to analyze factors and impacts associated with delayed presentation.
Results
This analysis included 2405 BC pts with pathological diagnosis from February 2001 to July 2023. The median time from symptom onset to the first presentation to a healthcare professional was 1.0 month (IQR 0.3-5.0). the proportion of delayed presentation (intervals≥3 months) was 28.4%. The median interval among pts with delayed presentation was 12.0 months (IQR 6.0, 24.0). MVA revealed that lower education levels (OR 1.37 [95% CI 1.13-1.67]; p=.002), lack of breast screening (OR 1.42 [95% CI 1.06-1.91]; p=.019), being farmers and unemployed (OR 1.36 [95% CI 1.01-1.83]; p=.045), and residing in county areas in western China (OR 1.71 [95% CI 1.38-2.12]; p<.001) were significantly associated with delayed presentation. The rank-sum test demonstrated that delayed presentation was linked with higher disease burden. The proportion of pts with delayed presentation diagnosed with stage III-IV (p<.001), tumor size≥2cm (p<.001), and more than three positive lymph nodes (p=.005) was significantly higher than those who sought timely care.
Conclusions
This analysis indicates that patient delays are influenced by social determinants of health. Lower socioeconomic status and education levels are risk factors for delayed presentation, and medical resources are unevenly distributed across regions. Therefore, promoting early presentation through advocacy, education, and policy should be prioritized, especially targeting socially deprived and less educated populations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1574P - Medical oncology residents mentors (MORM): A target for resiliency interventions
Presenter: David Paez
Session: Poster session 10
1575P - Smoke-free policies in outdoor areas: A potential cancer prevention strategy in Spain
Presenter: Karen Ramírez Cervantes
Session: Poster session 10
1576P - Smoking and lung cancer mortality in Italian men and women: 2003-2019
Presenter: Diego Serraino
Session: Poster session 10
1577P - Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
Presenter: Marta Garcia De Herreros
Session: Poster session 10
1578P - Perception of LMIC oncologists on meaningful cancer trial endpoints and value of cancer drugs
Presenter: Soumitra Shankar Datta
Session: Poster session 10
1579P - The Dutch national adolescent and young adult (AYA) cancer care network, a data driven learning healthcare system
Presenter: Winette Van Der Graaf
Session: Poster session 10
1580P - Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US
Presenter: Chadi Hage Chehade
Session: Poster session 10
1581P - AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC)
Presenter: Premal Thaker
Session: Poster session 10
1582P - Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)
Presenter: Lorena Incorvaia
Session: Poster session 10
1583P - Trial-level surrogacy of intermediate endpoints in adjuvant or neoadjuvant use of immune checkpoint blockade
Presenter: Luís Leite
Session: Poster session 10